Cell Therapy Account Management Specialist
Kyverna Therapeutics
Cell Therapy Account Management Specialist
Kyverna Therapeutics
T cell therapies for autoimmune diseases
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.
Reports to: VP of Sales
Territory: Mid-Atlantic / Northeast
Position Summary
Kyverna is seeking a highly motivated and experienced Cell Therapy Account Management Specialist to support the launch of our innovative cell therapy approach in autoimmune disease.
The Cell Therapy Account Management Specialist will serve as the commercial account lead for designated treatment centers, academic institutions, community practices, and referral networks within an assigned geography. This individual will drive demand and execute strategic account plans designed to build awareness, facilitate appropriate patient identification and referral, support treatment-center readiness, and drive appropriate adoption of Kyverna's cell therapy owning the performance of the assigned geography.
The total target cash compensation for this position is $280,000 to $320,000 USD annually. This range represents our reasonable estimate of the compensation we expect to offer for the position. Actual compensation may vary based on a number of factors, including, without limitation, an individual’s education, experience, tenure, skills and abilities, as well as internal equity and alignment with applicable market data.
This position is also eligible for Company benefits and participation in the Company’s stock plan.
T cell therapies for autoimmune diseases
Kyverna Therapeutics develops cell therapies for autoimmune diseases. The company uses synthetic biology, immunology, and cell engineering to create engineered T cells designed to target and modulate the root causes of autoimmunity. Its therapies are intended to be given by a single infusion to achieve long-lasting disease control, reducing or eliminating the need for ongoing treatments. Kyverna pursues in-licensing and collaboration opportunities to broaden its technology and capabilities and to advance its therapies toward patients through development and sales to patients and healthcare providers. The core goal is to provide durable, well-tolerated treatments that can offer substantial, long-term relief for people with autoimmune diseases.
Explore more opportunities at Kyverna Therapeutics